A drug’s potency, which is a critical quality attribute, is determined by examining biological activity at the cellular level. Cell-based assays are available to measure this activity. However, selecting, developing, validating, and performing the appropriate assay demands highly-specialized expertise. This work should only be entrusted to GMP laboratories with considerable proven experience.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
In this webinar, speaker Christopher Gilmer introduces microbiological testing for raw materials, APIs, and finished products, discusses the validation of methods and product testing requirements, and clarifies general procedures to investigate unexpected results.
The emergence of global pandemics has led to an expansion of studies focused on vaccine development for infectious agents. Moreover, breakthroughs in understanding the immune system in recent years have brought a new wave of treatments using immune system modulators and immunotherapies. The ELISpot assay is a powerful tool in addressing the bioanalytical needs of vaccine development, immunotherapies, and gene therapies. Tremendous global harmonization efforts have been carried out to create optimized protocols and guidelines for ELISpot assays. Successes in these efforts are now being transferred to other areas in which there is an urgent need for compliant, high-throughput image acquisition and analysis systems.
To ensure good data yield, there are challenges encountered during NGS operations, especially with poor quality RNA or DNA material, which is a common scenario for clinical samples. In this poster, we showcase three key tricks during the NGS operations to generate consistent data with high quality.